within Pharmacolibrary.Drugs.D_Dermatologicals.D02B_ProtectivesAgainstUvRadiation.D02BB02_Afamelanotide;

model Afamelanotide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 5.555555555555555e-07,
    adminDuration = 600,
    adminMass = 16 / 1000000,
    adminCount = 1,
    Vd = 0.06,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Afamelanotide</td></tr><tr><td>ATC code:</td><td>D02BB02</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>16</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>60</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Afamelanotide is a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH) used for the treatment of erythropoietic protoporphyria (EPP) to reduce photosensitivity and phototoxic reactions. It is administered as a subcutaneous implant and is approved for use in the European Union, Australia, and the United States.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adults based on available public summaries and regulatory documents. No full peer-reviewed population PK modeling study available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D02BB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Afamelanotide;
